IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of **Philippe Becourt, et al**

Application No.: 10/735,538

Pharmaceutical Formulation Having A

Filed: December 12, 2003

Masked Taste And Method For The Production Thereof

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-

Not Yet Assigned

Not Yet Assigned

Mar

Examiner:

Art Unit:

PE Title:

 \boxtimes

<u>INFORMATION DISCLOSURE STATEMENT</u> <u>UNDER 37 C.F.R. 1.56, 1.97 AND 1.98</u>

Mail Stop Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

(b)	This Information Disclosure Statement is filed after the period set forth in 37 C.F.R						
	1.97	(b), but is believed to be filed before the mailing date of a final action under §1.113					
	or a notice of allowance under §1.311, whichever occurs first.						
	(1)	The undersigned attorney certifies that each item of information contained in this					
		Information Disclosure Statement was cited in a communication from a foreign					
		patent office in a counterpart foreign application not more than three months prior					
		to the filing of this statement;					
	(2)	The undersigned attorney certifies that no item of information contained in this					
		Information Disclosure Statement was cited in a communication from a foreign					
		patent office in a counterpart foreign application or, to the knowledge of the					
		undersigned attorney after making reasonable inquiry, was known to any					
		individual designated in §1.56(c) more than three months prior to the filing of this					
		statement; or					
	(3)	This Information Disclosure Statement is accompanied by a transmittal letter in					
		which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is					
		authorized.					

Based on the new USPTO procedures, it is not required to submit copies of U.S. Patents and U.S. publications for all applications filed after June 30, 2003. Therefore, a copy of one (1) U.S. Patent Document listed on the attached PTO-1449 form is not enclosed with this Information Disclosure Statement.

Respectfully submitted,

Balaram Gupta, Reg. No. 40,009 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-3364 Telefax (908) 231-2626

Aventis Docket No. 2551 US CNT

Please type	a plus	sign	(+)	inside	this box	→	V
-------------	--------	------	-----	--------	----------	---	---

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCI Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known					
Application Number 10/735,538					
Filing Date	12-12-2003				
First Named Inventor	PHILIPPE BECOURT, ET AL				
Group Art Unit					
Examiner Name					
Attorney Docket Number	2551 - US - CNT				

	U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	U.S. Paten Number	Kind Code ² (if known)	Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		5,084,278		MEHTA	01-28-1992				
					 				
						<u> </u>			
_									
					1				
				•					
_									
-									
		<u> </u>							
					1	N 178			

	FOREIGN PATENT DOCUMENTS									
Examiner Initials	Cite 'No.1	Foreign Patent Document Kind Code ⁵ Office ³ Number ⁴ (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ ⁶			
		EP	0293885		FU LU, ET AL	12-07-1988				
		JP	63-150220			06-22-1988				
		wo	99/17742		CUMMING, ET AL	04-15-1999				
<u> </u>							All the state of t	 		
\vdash		-						-		

Examiner	Date	
Signature	Considered	

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.